久久一区二区三区四区_欧美高清dvd_日韩欧美在线看_国产精品欧美一区二区_av天天看_欧美精品免费观看二区

美國Pulmatrix  
Pulmatrix公司，一個臨床階段的生物制藥公司，開發用于治療，預防和傳輸控制的傳染病和進步呼吸系統疾病的吸入療法。它提供吸入呼吸道襯調制陽離子藥物，刺激呼吸道內的宿主防御機制來治療和預防流感，鼻病毒，慢性肺疾病。該公司成立于2003年，總部設在美國馬薩諸塞州列克星敦。

Pulmatrix is a clinical stage biotechnology company with an inhaled dry powder platform advancing a new generation of inhaled therapeutics. The platform, called iSPERSE (inhaled small particles easily respirable and dispersible), represents a new paradigm in inhaled drug delivery based on unique properties: dense, high drug load engineered particles with highly efficient dispersibility and delivery to the airways. The iSPERSE powders can be used with an array of dry powder inhaler technologies and can be formulated with virtually any drug substance including our novel iCALM (inhaled Cationic Airway Lining Modulators) therapies, small molecules, biologics, and multi-drug combinations.

With the iSPERSE platform, Pulmatrix is developing a broad pipeline to prevent and treat a range of respiratory diseases with significant unmet medical needs including chronic obstructive pulmonary disease (COPD), cystic fibrosis, idiopathic pulmonary fibrosis, and severe asthma. The company has demonstrated comprehensive data showing that iSPERSE can be applied to a broad range of therapeutic compounds ranging from small molecules to proteins and including our lead dry powder iCALM therapies. Further optimization of select iSPERSE therapeutic formulations across a range of drug loads for scale up, manufacturing conditions, and stability testing has yielded promising results for the potential of the platform. Potential advantages of iSPERSE platform therapeutics on clinical treatment efficacy include reduced total inhaled powder mass, enhanced dosing efficiency, reduced cost of goods and improved safety and tolerability profiles.

Proprietary iCALM therapies comprise combinations of cationic salts designed to trigger multiple mechanisms that harness the body’s natural host defense and immune response in the airway to reduce inflammation, safely prevent and treat respiratory infections, and prevent acute exacerbations in patients with chronic inflammatory airway disease. The company’s lead dry powder iCALM drug candidate is the first clinical candidate based upon the iSPERSE platform. A host-targeted therapy, iCALM is designed to have broad application for respiratory diseases such as COPD, asthma, and cystic fibrosis and respiratory infections including influenza, influenza-like illness (ILI), rhinovirus, ventilator associated pneumonia (VAP) and respiratory syncytial virus (RSV). Pulmatrix has successfully completed Phase 1 safety and tolerability testing of our lead dry powder iCALM drug candidate in human studies including allergic asthmatics and COPD patients. The company has active clinical programs in COPD and cystic fibrosis.